MultiHance clinical pharmacology: Biodistribution and MR enhancement of the liver

Spinazzi, Alberto; Lorusso, Vito; Pirovano, Gianpaolo; Taroni, Paola; Kirchin, Miles A.; Davies, Alexandra

doi:10.1016/s1076-6332(98)80069-x

Cited by 74 publications

(69 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MultiHance is excreted up to 50% via the hepatobiliary system in rats [28] causing faster excretion and thereby a lower AUC. This difference compared to the other GBCAs is not seen in humans, where the hepatobiliary excretion of MultiHance accounts only for 0.6-4% [29]. Therefore, the observations regarding the Gd concentration after treatment with MultiHance in the rat model may not be an accurate predictor of the clinical situation.…”

Section: Discussionmentioning

confidence: 90%

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions

et al. 2008

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions

et al. 2008

View full text Add to dashboard Cite

“…In other words, the first-generation agents are essentially interchangeable for the majority of applications (8). MultiHance, the second-generation linear Gd chelate, has 50% higher relaxivity than the early agents (in blood at 1.5T, higher at lower field strengths), and 2% to 4% of the injected dose is excreted in the bile (9).…”

Section: Basic Pharmacologymentioning

confidence: 99%

MR contrast agents: Physical and pharmacologic basics

Lin

Brown

2007

Magnetic Resonance Imaging

223

175

View full text Add to dashboard Cite

Since approval of the first magnetic resonance (MR) contrast agent was granted in 1988, there has been remarkable growth in the utilization of intravenous gadolinium (Gd)-based agents. Currently it is estimated that nearly half of all MR studies performed are contrast-enhanced. Despite containing a toxic heavy metal, these agents have proven to be not only an effective diagnostic adjunct to non-enhanced MRI, but also remarkably well tolerated and safe. As a result, conventional wisdom has been that MR contrast media are "biologically inert," a notion that is clearly false. Ultimately, it is the radiologist's responsibility to understand the potential adverse effects of Gd-based agents and the special situations in which they are likely to occur; however, the basic pharmacology of contrast agents is generally not included in medical school curricula or formally taught in residency. The purpose of this review is to discuss the mechanism of action of MR contrast agents and relevant aspects of their clinical pharmacology, including effects on the cardiovascular and renal systems, potential laboratory errors, and special situations involving women and children. We also briefly discuss the issue of nephrogenic systemic fibrosis (NSF).

show abstract

“…This selective uptake is manifested through a canalicular multispecific organic anion transporter competing with bromosulfophthalein and bilirubin (15). Gd-BOPTA taken up selectively by hepatocytes is excreted into bile without biological processing.…”

Section: Discussionmentioning

confidence: 99%

Initial experience on utility of gadobenate dimeglumine (Gd‐BOPTA) enhanced T1‐weighted MR cholangiography in diagnosis of acute cholecystitis

Akpınar

Türkbey

Karçaaltıncaba

et al. 2009

Magnetic Resonance Imaging

View full text Add to dashboard Cite

PurposeTo investigate the feasibility of the use of gadobenate dimeglumine (also known as Gd‐BOPTA) ‐enhanced T1‐weighted MR cholangiography in diagnosis of acute cholecystitis.Materials and MethodsThis prospectively designed institutional review board‐approved HIPAA‐compliant study was done between January and November 2007. We included 11 consecutive patients (7 male, mean age 59 years) who presented to the emergency room with acute right upper quadrant pain and with equivocal physical examination and/or ultrasound findings. The control group included 15 patients who underwent liver MRI with Gd‐BOPTA. All patients underwent contrast‐enhanced (CE) MR cholangiography examinations. CE‐MR cholangiography was performed on a 1.5 Tesla magnet using 3D T1‐weighted high resolution isotrophic volume examination (THRIVE) obtained at the 90th min after intravenous injection of Gd‐BOPTA. Imaging features detected on CE‐MR cholangiography were correlated with operative and histopathologic findings.ResultsIn the control group, GD‐BOPTA was visualized within the gallbladder in all subjects. For the study group, gallstones were present in nine patients (n = 7 both in gallbladder and cystic duct, n = 1 only in gallbladder, n = 1 only in cystic duct) on MRCP. Hydropic gallbladder was detected in seven patients, significant wall thickening in seven patients, and pericholecystic free fluid in 6 patients. On delayed phase CE cholangiography, significant enhancement of gallbladder wall was seen in 10 patients, and contrast agent excretion into gallbladder was absent in all patients. Surgery was performed in 10 patients, and cholecystostomy was done in 1 patient. Surgery and histopathology findings were consistent with cholecystitis in all patients.ConclusionIn addition to anatomical assessment, Gd‐BOPTA‐enhanced MR cholangiography can provide functional evaluation similar to HIDA scintigraphy in diagnosing acute cholecystitis in patients with acute right upper quadrant pain and equivocal findings. J. Magn. Reson. Imaging 2009;30:578–585. © 2009 Wiley‐Liss, Inc.

show abstract

MultiHance clinical pharmacology: Biodistribution and MR enhancement of the liver

Cited by 74 publications

References 7 publications

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions

MR contrast agents: Physical and pharmacologic basics

Initial experience on utility of gadobenate dimeglumine (Gd‐BOPTA) enhanced T1‐weighted MR cholangiography in diagnosis of acute cholecystitis

Contact Info

Product

Resources

About